Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

Oh no… not more training

Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way

Fox&Cat

A magic milestone: Sally’s 10-year #LucidLife workiversary

Our people define our culture and there is no better example of what we are striving to achieve than what Sally Ratcliffe, Scientific Director, Lucid Group, has demonstrated over the...

Lucid Group Communications Limited

- PMLiVE

UK-based challenge study to re-expose healthy adults to COVID-19

Study will enrol participants aged 18-30 who have previously been infected with COVID-19

- PMLiVE

Italy accelerates the path towards digital therapeutics implementation

PME talks to Roberto Ascione, Gualberto Gussoni and Giuseppe Recchia about the advancement of digital therapeutics in Italy

Roche Basel Switzerland

Roche’s Ocrevus shows significant benefit in early-stage MS patients

The data was presented virtually at the American Academy of Neurology annual meeting

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

- PMLiVE

Moderna COVID-19 vaccine shortfall could affect UK supply

But deliveries to the EU and Switzerland are not affected by the supply issues

- PMLiVE

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Decision prompted by the ‘evolving variant landscape’ in the US

Novartis day

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

New post hoc data comes from phase 3 ASCLEPIOS trials

- PMLiVE

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris

- PMLiVE

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

Company is aiming to receive European approval in June

- PMLiVE

Virtually, the same: Is it time to rethink congress strategy?

by Jonathan Andrew

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links